杨梦霞;芦殿荣;朱世杰;王宁军;

• 1:中国中医科学院望京医院
• 2:北京中医药大学

摘要(Abstract)：

目的 通过网络药理学方法研究旋覆代赭汤治疗化疗性恶心呕吐（CINV）作用机制。方法 利用TCMSP、SymMap、TCMID和TCM Database@Taiwan数据库筛选药物有效成分，利用Swiss Target Prediction数据库检索旋覆代赭汤靶点；通过GengCards、DisGeNet、Drugbank及OMIM数据库检索CINV靶点，并将药物和疾病靶点进行映射，通过Cytoscape软件可视化并筛选出关键靶点，对潜在治疗靶点进行GO和KEGG富集分析。结果 旋覆代赭汤主要有效成分有119个，包含309个靶点。CINV靶点有830个，其中108个是潜在治疗靶点，肿瘤坏死因子（TNF）、白细胞介素-1β(IL-1β)、环加氧酶2(PTGS2)和基质金属蛋白酶2(MMP2)等为关键靶点。通过GO和KEGG富集分析发现旋覆代赭汤治疗CINV是通过HIF-1、PI3K/Akt和TNF等信号通路发挥止吐作用。结论 通过网络药理学发现旋覆代赭汤治疗CINV的作用机制复杂，涉及多靶点、多通路，为今后研究提供了新思路。

关键词(KeyWords)： 化疗性呕吐;旋覆代赭汤;网络药理学;作用机制

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81973640）

作者(Authors): 杨梦霞;芦殿荣;朱世杰;王宁军;

参考文献(References)：

• [1]Shankar A,Roy S,Malik A,et al.Prevention of chemotherapy-induced nausea and vomiting in cancer patients[J].Asian Pac J Cancer Prev,2015,16(15):6207-6213.
• [2]Viale PH,Grande C,Moore S.Efficacy and cost:avoiding undertreatment of chemotherapy-induced nausea and vomiting[J].Clin J Oncol Nurs,2012,16:E133-141.
• [3]Adel N.Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies[J].Am J Manag Care,2017,23(14):S259-S265.
• [4]Hsieh RK,Chan A,Kim HK,et al.Baseline patient characteristics,incidence of CINV,and physician perception of CINVincidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries[J].Support Care Cancer,2015,23:263-272.
• [5]Osaki A,Inoue K,Sakai H,et al.A dose-finding randomized PhaseⅡstudy of oral netupitant in combination with palonosetron.75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy[J].Jpn J Clin Oncol,2019(49):121-129.
• [6]崔艺馨，米继伟，唐潇然，等.小半夏汤联合穴位针刺治疗乳腺癌术后化疗相关性恶心呕吐的临床研究[J].中国医药，2021,16(8):1231-1235.
• [7]陈玲玲，韩涛，刘兆喆，等.加味旋覆代赭汤防治乳腺肿瘤化学治疗相关消化道反应的疗效观察[J].中国临床实用医学，2017,11(1):2022.
• [8]钟欢，李杳瑶，孙铜林，等.旋覆代赭汤防治化疗性呕吐的疗效观察及最佳配比研究[J].湖南中医杂志，2019,35(12):10-13.
• [9]Mehendale S,Aung H,Wang CZ,et al.Scutellaria baicalensis and a constituent flavonoid,baicalein,attenuate ritonavir-induced gastrointestinal side-effects[J].J Pharm Pharmacol,2007,59(11):1567-1572.
• [10]Ribeiro AR,do Nascimento Valen?a JD,da Silva Santos J,et al.The effects of baicalein on gastric mucosal ulcerations in mice:Protective pathways and anti-secretory mechanisms[J].Chem Biol Interact,2016(260):33-41.
• [11]Beber AP,de Souza P,Boeing T,et al.Constituents of leaves from Bauhinia curvula Benth.Exert gastroprotective activity in rodents:role of quercitrin and kaempferol[J].Inflammopharmacology,2018,26(2):539-550.
• [12]Li Y,Zhang J,Zhang L,et al.Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula[J].J Ethnopharmacol,2015(174):45-56.
• [13]Wong J,Tran LT,Lynch KA,et al.Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice[J].Cancer Biol Ther,2018,19(1):87-96.
• [14]Braun TP,Szumowski M,Levasseur PR,et al.Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle[J].PLoS One,2014,9(9):e106489.
• [15]Grossberg AJ,Zhu X,Leinninger GM,et al.Inflammation-induced lethargy is mediated by suppression of orexin neuron activity[J].J Neurosci,2011,31(31):11376-11386.
• [16]Smith LB,Leo MC,Anderson C,et al.The role of IL-1βand TNF-αsignaling in the genesis of cancer treatment related symptoms(CTRS):a study using cytokine receptor-deficient mice[J].Brain Behav Immun,2014,38:66-76.
• [17]Ugan RA,Un H,Kose D,et al.Can aprepitant used for nausea and vomiting be good gastrointestinal complaints[J].Naunyn Schmiedebergs Arch Pharmacol,2020,393(12):2463-2472.
• [18]Kim A,Im M,Yim NH,et al.Aqueous extract of bambusae caulis in taeniam inhibits PMA-induced tumor cell invasion and pulmonary metastasis:Suppression of NF-κB activation through ROS signaling[J].PLo S One,2013,8(10):e78061.
• [19]Guo JC,Li WJ,Wu YX,et al.Meclizine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis partially by upregulating PXR[J].Front Pharmacol,2017,8:693.
• [20]Courtnay R,Ngo DC,Malik N,et al.Cancer metabolism and the Warburg effect:the role of HIF-1 and PI3K[J].Mol Biol Rep,2015,42:841-851.
• [21]Noorolyai S,Shajari N,Baghbani E,et al.The relation between PI3K/AKT signalling pathway and cancer[J].Gene,2019,698:120-128.
• [22]BT Hennessy,DL Smith,PT Ram,et al.Exploiting the PI3K/AKT pathway for cancer drug discovery[J].Nat Rev Drug Discov,2005,4:988-1004.
• [23]DP Sutherlin,L Bao,M Berry,et al.Discovery of a potent,selective,and orally available class I phosphatidylinositol 3-kinase(PI3K）/mammalian target of rapamycin(m TOR)kinase inhibitor(GDC-0980)for the treatment of cancer[J].J Med Chem,2011,54:7579-7587.
• [24]A Hollebecque,A Clamp,L Horsley,et al.A phase 1 study evaluating the pharmacokinetics(PK)and pharmacodynamic(PD)activity of the dual PI3K/m TOR inhibitor GDC-0980administered once weekly(QW)[R].American Association for Cancer Research,Orlando,FL,2011,42(18):747-751.
• [25]R Millham,B Houk,G Borzillo.First-in-patient study of PF-049691502,a small molecule intravenous dual inhibitor of PI3K and m TOR in patients with advanced cancer:update on safety,efficacy,and pharmacology[C]//AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics.Molecular Cancer Therapeutics,San Francisco,CA,2011,10:Abstr nr B163.